Abiopharma

🔍 Allouche Danny Gilad (Executive)

Company: Avery Dennison Corp (AVY)

Report Date: 2026-09-01

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-09-01 | Code: H | nature_of_ownership: Trust | shares_owned_after: 23,153.00
• Acquired 351 shares of Suppl. 2026 PU Award (Derivative)
  Date: 2026-09-01 | Code: A | Expires: 2029-03-01 | Exercise: 2029-03-01 | equity_swap_involved: 0 | shares_owned_after: 351.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 243 shares of Suppl. 2026 RSU Award (Derivative)
  Date: 2026-09-01 | Code: A | Expires: 2030-03-01 | Exercise: 2027-09-01 | equity_swap_involved: 0 | shares_owned_after: 243.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 2,866 shares of 2026 Special RSU Award (Derivative)
  Date: 2026-09-01 | Code: A | Expires: 2029-06-01 | Exercise: 2029-06-01 | equity_swap_involved: 0 | shares_owned_after: 2,866.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Supplemental 2026 award of performance units (PUs), which vest at the end of fiscal year 2028 provided certain performance objectives are met as determined by the Compensation Committee in February 2029. Each PU represents a contingent right to receive one share of common stock.
• F2: Supplemental 2026 award of restricted stock units (RSUs), which vest 25% on September 1, 2027 and each of March 1, 2028, 2029 and 2030. Each RSU represents a contingent right to receive one share of common stock.
• F3: One-time special award of RSUs that cliff-vest on June 1, 2029. Each RSU represents a contingent right to receive one share of common stock.